We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

51 hedge funds and large institutions have $9.31M invested in Matinas BioPharma in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

2% more funds holding

Funds holding: 50 → 51 (+1)

0.01% less ownership

Funds ownership: 0.25% → 0.24% (-0.01%)

26% less capital invested

Capital invested by funds: $12.6M → $9.31M (-$3.29M)

57% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 14

Holders
51
Holders Change
+1
Holders Change %
+2%
% of All Funds
0.8%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
14
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Wells Fargo
Wells Fargo
California
+$261K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$71.9K
3
VF
Virtu Financial
New York
+$42.1K
4
BlackRock
BlackRock
New York
+$18.5K
5
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
+$9.35K

Top Sellers

Rank Fund Capital Flow
1
NRS
Neville Rodie & Shaw
New York
-$278K
2
BCM
Bridgeway Capital Management
Texas
-$166K
3
SIG
Sargent Investment Group
Maryland
-$153K
4
Millennium Management
Millennium Management
New York
-$90.5K
5
Jane Street
Jane Street
New York
-$27.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$3.14M -$18.5K -795 -0.5%
SIG
2
Sargent Investment Group
Maryland
$1.41M -$153K -6,580 -8%
BlackRock
3
BlackRock
New York
$903K +$18.5K +795 +2%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$705K +$71.9K +3,082 +9%
AWA
5
Arkadios Wealth Advisors
Georgia
$504K – – –
NRS
6
Neville Rodie & Shaw
New York
$417K -$278K -11,923 -34%
JEST
7
JTC Employer Solutions Trustee
Jersey
$275K – – –
State Street
8
State Street
Massachusetts
$256K – – –
LPL Financial
9
LPL Financial
California
$223K -$6.71K -288 -2%
SCA
10
STALEY CAPITAL ADVISERS
Pennsylvania
$216K – – –
Wells Fargo
11
Wells Fargo
California
$204K +$261K +11,199 +8,484%
MSFS
12
Main Street Financial Solutions
Pennsylvania
$144K – – –
Northern Trust
13
Northern Trust
Illinois
$130K -$536 -23 -0.3%
CCM
14
Courage Capital Management
Tennessee
$119K – – –
PAG
15
Private Advisor Group
New Jersey
$77K +$9.33K +400 +10%
BCM
16
Bridgeway Capital Management
Texas
$70.7K -$166K -7,138 -64%
PTP
17
Platform Technology Partners
New York
$64.1K – – –
Bank of New York Mellon
18
Bank of New York Mellon
New York
$59.4K -$233 -10 -0.3%
Renaissance Technologies
19
Renaissance Technologies
New York
$53K -$12.1K -517 -15%
MWM
20
Modera Wealth Management
New Jersey
$34K – – –
VF
21
Virtu Financial
New York
$33K +$42.1K +1,806 New
CDH
22
Charles D. Hyman
$29K – – –
Charles Schwab
23
Charles Schwab
California
$28.2K – – –
BFG
24
Bleakley Financial Group
New Jersey
$21.6K – – –
SS
25
Simplicity Solutions
Minnesota
$21.6K – – –
1
2 3

MTNB Hedge Fund Activity: Q2 2023 in Review

51 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q2 2023, worth a combined $9.31M — down 26% from $12.6M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new MTNB positions and 4 closed out — a net gain of 1 holder — while 6 added to existing stakes and 14 trimmed.

The largest buyer was Wells Fargo, adding an estimated $261K. The largest seller was Neville Rodie & Shaw, cutting an estimated $278K.

  • 51 institutional investors held Matinas BioPharma (MTNB) as of Q2 2023, up from 50 in Q1 2023.
  • Funds reported $9.31M of Matinas BioPharma stock for Q2 2023, down 26% quarter-over-quarter.
  • 5 funds opened new Matinas BioPharma positions in Q2 2023 and 4 closed out, a net change of +1 holder.
  • The largest Matinas BioPharma buyer in Q2 2023 was Wells Fargo, an estimated $261K added.
  • The largest Matinas BioPharma seller in Q2 2023 was Neville Rodie & Shaw, an estimated $278K sold.

Based on aggregated 13F filings for Q2 2023.